Home    Contact    Sitemap    Search    
  Print page    
  
News
2010.03.08   Shares purchased by employees and notification of trade  
2010.02.19   Presentation 4th Quarter 2009  
2010.02.19   Results 4th quarter and full year 2009  
2010.02.16   Presentation of the annual report 2009  
2010.01.13   Hexvix® receives reimbursement approval in Germany  
2010.01.06   Inclusion completed in phase II study with Visonac™ for acne  
2010.01.06   Financial calendar 2010  
2009.12.31   Photocure received positive response from FDA on the New Drug Application (NDA) for Hexvix® for detection of bladder cancer  
2009.12.18   FDA Advisory Committee voted favourably to Hexvix® application in USA  
2009.11.26   Photocure granted patent in Europe and Russia for Visonac™ in the treatment of acne  
2009.11.25   Extraordinary General Meeting  
2009.11.23   Shares purchased by employees  
2009.11.20   FDA has posted an Advisory Committee meeting with Photocure to discuss Hexvix® NDA  
2009.11.03   Notice of extraordinary general meeting  
2009.10.28   Capital Markets Day Presentations  
2009.10.28   3rd quarter presentation  
2009.10.28   Share buy back and proposed extraordinary dividend of NOK 4.00/share  
2009.10.27   Information memorandum regarding Photocures divestment of Metvix®  
2009.10.20   Invitation to presentation of 3rd quarter report 2009 and Capital Markets Day  
2009.10.07   Photocure divests Metvix® to Galderma for EUR 51 million  
2009.10.01   Invitation to presentation of Photocure's divestment of Metvix®  
2009.10.01   Presentation of Photocures divestment of Metvix®  
2009.09.29   Market making agreement  
2009.08.31   Hexvix® has been granted priority review by the FDA  
2009.08.14   Presentation 2nd quarter report  

 
  Photocure ASA, Hoffsveien 48, NO-0377 Oslo, Norway. Telephone: +47 22 06 22 10 Fax: +47 22 06 22 18